
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences is attractive because it combines a de-risked balance sheet with meaningful pipeline expansion, ending 2Q26 with $320.4 million in cash and investments and expected funding into 2029, including the first $75 million Gilead collaboration extension payment due in 4Q26. Its lead ABI-6250 program now has two shots on goal, with a Phase 2 HDV trial expected by year-end 2026 and a new Phase 2 basket trial in PBC and PSC anticipated in 1Q27, while EASL 2026 data showed a four-day half-life, about seven-fold accumulation, and no pruritus despite dose-dependent bile-acid increases. The Gilead-selected GS-1179 program also gains optionality in recurrent genital herpes and potentially HIV PrEP, and the company’s model assigns a 70% approval probability to ABI-6250 and 70% to ABI-5366, supporting a favorable long-term fundamental view.
Bears say
Assembly Biosciences is viewed negatively because, despite $226.6M in cash at the end 1Q 2026 and the May 2026 offering that raised about $115M gross, the company still appears dependent on external financing before reaching sustainable profitability. Management’s cash runway into 2028 excludes possible GILD payments and warrant exercises, while profitability is not expected on a continuing basis until 2032, implying likely dilution from another capital raise. The valuation also remains highly exposed to clinical and commercial execution risk for ABI-5366, ABI-1179, and ABI-6250, as any delays, reimbursement issues, or weak commercialization could materially reduce sales potential.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Assembly Biosciences (ASMB) Forecast
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares